Clinical features in patients with the familial early onset forms and the sporadic forms of Alzheimers disease are similar, although the course of deterioration may be different. It would be very informative to examine the drug response of patients with Alzheimers disease by a certain genotype to find evidence favouring genotype-specific drug responses that may indicate genetically defined phenotypic differences in alzheimers disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Rosi XR tablets
Placebo
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom
Change in global and regional cerebral glucose metabolism/Cerebral Metabolic Rate for glucose (CMRglu) as measured by the ratio of Ki to K1
Time frame: at baseline and 12 months.
Changes in global and regional CMRglu as measured by [18F]FDG uptake.
Time frame: between baseline and 12 month point
Global changes in brain structure from baseline as measured by structural MRI from baseline.Vital signs and ECGs.
Time frame: throughout study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.